School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou 510275, People's Republic of China.
J Med Chem. 2012 Oct 11;55(19):8549-58. doi: 10.1021/jm301189c. Epub 2012 Oct 1.
A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyrimidinone have been discovered by a combination of structure-based design and computational docking. This procedure significantly saved the load of chemical synthesis and is an effective method for the discovery of inhibitors. The best compound 28 has an IC(50) of 21 nM and 3.3 μM, respectively, for PDE9 and PDE5 and about 3 orders of magnitude of selectivity against other PDE families. The crystal structure of the PDE9 catalytic domain in complex with 28 has been determined and shows a hydrogen bond between 28 and Tyr424. This hydrogen bond may account for the 860-fold selectivity of 28 against PDE1B, in comparison with about 30-fold selectivity of BAY73-6691. Thus, our studies suggest that Tyr424, a unique residue of PDE8 and PDE9, is a potential target for improvement of selectivity of PDE9 inhibitors.
通过结构为基础的设计和计算对接的组合,我们发现了一系列新的包含 6-氨基-吡唑并嘧啶酮结构的磷酸二酯酶-9(PDE9)抑制剂。该方法大大减少了化学合成的负荷,是发现抑制剂的有效方法。最佳化合物 28 对 PDE9 和 PDE5 的 IC50 分别为 21 nM 和 3.3 μM,对其他 PDE 家族的选择性约为 3 个数量级。已经确定了 PDE9 催化结构域与 28 复合物的晶体结构,并显示出 28 与 Tyr424 之间的氢键。与 BAY73-6691 相比,这种氢键可能导致 28 对 PDE1B 的 860 倍选择性,而对 PDE1B 的选择性约为 30 倍。因此,我们的研究表明,Tyr424 是 PDE8 和 PDE9 的独特残基,是提高 PDE9 抑制剂选择性的潜在靶标。